Screener
CRISPR Therapeutics CRSP EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's EBITDA margin?
- CRISPR Therapeutics (CRSP) reported EBITDA margin of -15,289.6% in Q1 2026.
- How has CRISPR Therapeutics's EBITDA margin changed year-over-year?
- CRISPR Therapeutics's EBITDA margin decreased by 1165.3% year-over-year, from -1,208.3% to -15,289.6%.
- What is the long-term trend for CRISPR Therapeutics's EBITDA margin?
- Over 3 years (2020 to 2025), CRISPR Therapeutics's EBITDA margin has grown at a -27.4% compound annual growth rate (CAGR), from -48,018.2% to -18,378.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about CRISPR Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude